Physicians’ Opinions Survey on FDA’s Bydureon Approval

2012-03-06

Report Description

Physicians were asked to assess their impressions of Bydureon in terms of efficacy, safety, tolerability, expected use, and other important factors. Key questions are broken down by specialty or familiarity to highlight difference in physician perceptions

Highlights

Datamonitor anticipates that the initial enthusiasm will ultimately be muted once physicians gain experience with the drug. Nevertheless, a once-weekly antidiabetic agent clearly represents an attractive option for type 2 diabetes patients, and physicians expect the drug to be a welcome addition to their armamentarium.

FDA’s Bydureon Approval

Published: February 2012
Price
: Single User License US$3800            Corporate User License – US$9500

                    Request Sample


Your key questions answered
  • Assess physicians’ opinions of Bydureon as compared with Amylin’s twice-daily Byetta (exenatide) and Novo Nordisk’s once-daily Victoza (liraglutide)
  • Determine physicians’ expectations for Bydureon’s uptake, line of therapy, and use in combination with other antidiabetics
  • Evaluate how Bydureon may expand the overall market for GLP-1 agonists

Table of Contents

BYDUREON FDA APPROVAL: PHYSICIAN OPINION
Background

SURVEY RESULTS
Demographics
Limited familiarity with PCPs could present a marketing challenge
Impressions of Bydureon’s efficacy differ based on familiarity
Tolerability issues trump safety concerns among physicians familiar with Bydureon
High expectations for Bydureon use will likely come down with increased experience
Endocrinologists expect to use Bydureon in earlier line of therapy compared to PCPs
Combination use with oral antidiabetics is likely
Physicians expect Bydureon to expand the GLP-1 agonist market
Conclusion

APPENDIX
Report methodology
Datamonitor consulting

Disclaimer

List of Figures

Figure: On average, how many patients with type 2 diabetes do you treat per month?
Figure: How familiar are you with Bydureon (once-weekly exenatide)?
Figure: For each attribute below, please select the one drug that you would prefer to prescribe, based on performance (or predicted performance) on that attribute
Figure: Please select the one drug that you would prefer to prescribe, based on efficacy (HbA1c lowering ability)
Figure: Please rank the following potential safety (and tolerability) issues you are most concerned about with Bydureon on a scale of 1 to 7, where 1 is the issue of greatest concern and 7 is the issue of least concern
Figure: Please select the one drug that you would prefer to prescribe, based on injection device
Figure: Where in the treatment algorithm do you think you will most commonly prescribe Bydureon?
Figure: Please consider your hypothetical Bydureon-treated patient population a year post-launch. What percentage of the Bydureon-treated patient population do you expect to have previously been treated with each of the following options?
Figure: Please choose up to three drug classes with which Bydureon could be used in combination. If there are more than three classes, please select the three most likely
Figure: Please give your opinion on how the introduction of Bydureon, and any other market trends, will impact on the number of patients on GLP-1 agonists in the US

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
More Reports
Title Price Buy Now

Pharmaceutical Logistics Market in the APAC 2015-2019

Logistics deals with the procurement, planning, and implementation of activities in the forward and reverse logistics chain of an organization. The pharmaceutical industry uses logistics for the complete management of the way resources are acquired, stored, and moved to different end-user locations. The use of logistics helps the pharmaceutical industry to have a continual supply of drugs, equipment, and devices from suppliers and distributors in different locations. The analysts forecast the pharmaceutical logistics market in the APAC to grow at a CAGR of 10.45% over the period 2014-2019. Covered in this Report The report covers present scenario and the growth prospects of the pharmaceutical logistics market in the APAC for the period 2015-2019. The market is segmented based on t......
$2500

Pharmaceutical Packaging Market in North America 2015-2019

Packaging products are meant to protect perishable goods from damage and contamination. Pharmaceutical packaging products have strong barrier properties, are meant to be portable, and are available in both unit dosage and multi-dose formats. International regulations regarding safe drug delivery are enforced by regulatory bodies on drug manufacturers, which in turn fuels adoption of sustainable packaging. Various raw materials such as plastic resins, glass, paper and paperboard, and aluminum and other metals are used in the manufacture of pharmaceutical packaging. These packages are available in a variety of dimensions and forms. The analysts forecast pharmaceutical packaging market in North America to grow at a CAGR of 5.31 percent over the period 2014-2019. Covered in this Report ......
$2500

Global Systemic Lupus Erythematosus (SLE) Drugs Market 2015-2019

SLE is the most common form of lupus and is also called lupus. It is a chronic, autoimmune disease with signs and symptoms that can last for six months or for many years. It can affect any part of the body, such as the skin, joints, and organs (LFA, 2012). SLE occurs when the immune system produces autoantibodies, which attack and destroy healthy tissues in the body rather than foreign infectious agents. These autoantibodies cause inflammation, pain, and damage. It is also known as a disease of flare-ups and remissions and can range from mild to life threatening in severity. No cure for SLE yet exists. The analysts forecast Global SLE Drugs market to grow at a CAGR of 22.41 percent over the period 2014-2019. Covered in this Report This report covers the present scenario and the gr......
$2500

Global Gastrointestinal OTC Drugs Market 2015-2019

OTC drugs are medications that do not require a prescription. In contrast, prescription drugs can be sold only to consumers having a legal prescription. OTC drugs are carefully chosen by regulatory agencies to ensure their safety and efficacy. Gastrointestinal OTC drugs can be bought off-the-shelf. Gastrointestinal OTC drugs are used for indications such as GERD, vomiting, constipation, diarrhea, and flatulence. Some of the OTC drugs that are available for the treatment of gastrointestinal diseases are laxatives, anti-flatulents, H2-antaginists, anti-diarrheals, PPIs, and anti-emetics. The OTC drugs are not bound by regulatory guidelines, but need to comply with the drug monograph of a country. The analysts forecast global gastrointestinal OTC drugs market to grow at a CAGR of 1.48% ove......
$2500

Global Inflammatory Bowel Disease Market 2015-2019

Inflammatory bowel disease is a condition includes a group of autoimmune diseases such as Crohn's disease and ulcerative colitis. It causes chronic inflammation of a specific part or the entire GI tract. Both Crohn's disease and ulcerative colitis include symptoms such as severe persistent diarrhea, abdominal cramps and pain, rectal bleeding, fatigue, and weight loss. Inflammatory bowel disease can also prove to be life-threatening for the patients. Ulcerative colitis generally affects the colon, where inflammation and ulcers develop in the innermost lining of the colon and the rectum of a patient. Crohn's disease causes inflammation of the lining of the GI tract. The inflammation in Crohn's disease affects various areas of the GI tract such as the large intestine and small intestine, or b......
$3000

Global Pompe Disease Market 2015-2019

Pompe disease is a type of LSD. LSD refers to a group of diseases arising from the accumulation of specific substrates. LSDs are progressive and have variable age of onset and clinical symptoms. LSDs are inherited autosomal recessive disorders. Pompe disease has two broad sub-types: infantile-onset Pompe disease and adult-onset Pompe disease. Pompe disease occurs as a result of mutations in the GAA gene. These mutations are responsible for the preventing the action of the enzyme acid alpha-glucosidase, which is responsible for catabolizing glycogen, thereby allowing sugar to accumulate and reach toxic levels in the lysosomes of cells. The buildup of glycogen in certain organs and tissues, mostly in the muscles, hinders the normal functions of organs. Pompe disease is an autosomal recessive......
$2500

Healthcare IT (HIT) Market in the APAC Region 2015-2019

Healthcare providers are leveraging the usage of IT in their business processes. It has changed the way hospitals and physicians work; from the automation of simple processes in the Healthcare sector to its integration with the entire value chain of the Healthcare sector, HIT has come a long way. This development is focused on the Healthcare sector becoming more patient-centric. The analysts forecast HIT Market in APAC to grow at a CAGR of 16 percent over the period 2014-2019. Covered in this Report The HIT Market in APAC is categorized into two segments: Clinical IT and Non-clinical IT. This break-up is done on the basis of advanced nations and developing nations. The report, Healthcare IT (HIT) Market in the APAC Region 2015-2019, has been prepared based on an in-depth market......
$3000

Global Negative Pressure Wound Therapy Market 2015-2019

Negative pressure wound therapy is a technique that applies negative pressure to a wound to promote wound healing by removing the fluid and infectious materials from the wound. This therapy is helpful in treating various types of wounds such as acute wound and chronic wound. Negative pressure wound therapy system consists of a vacuum pump, a foam or gauze wound dressing, drainage tubing, and an adhesive film dressing to cover and seal the wounds. The analysts forecast Global Negative Pressure Wound Therapy market to grow at a CAGR of 7.97 percent over the period 2014-2019. Covered in this Report The report covers present scenario and the growth prospects of the Global Negative Pressure Wound Therapy market for the period 2015-2019. Based on technology, the market can be segmented ......
$2500

Global Melanoma Therapeutics Market 2015-2019

According to Melanoma Research Foundation, melanoma is usually, but not always, a cancer of the skin. Melanoma is defined as a cancer that occurs in melanocytes (cells that make the pigment melanin). Chest and back in men and legs in women are the most likely parts to be affected with melanoma. CM, MM, and OM are the three major categories of melanoma. The exact etiology of melanoma is unknown. According to the American Skin Association, the incidence of melanoma is increasing worldwide. The median age of diagnosis is 59 years and the median age of death due to melanoma is 67 years. The analysts forecast Global Melanoma Therapeutics market to grow at a CAGR of 15.40 percent over the period 2014-2019. Covered in this Report This report covers present scenario and the growth prospec......
$2500

Global Healthcare BPO Market 2015-2019

BPO is a segment of outsourcing, which consists of subcontracting the business processes of an organization to a third-party vendor that has the expertise in the required domains. It helps clients to increase their operational efficiency, concentrate on their core competencies, reduce time-to-market, obtain access to fresh talent and experience along with the latest technologies, and build an organization with an economical cost structure in the long run. The healthcare space has been witnessing the adoption of BPO services due to proven benefits, such as cost reduction, improved patient care services, and staff efficiency. The analysts forecast Global Healthcare BPO Market that comprises F&A BPO, HR BPO and CRM BPO to grow at a CAGR of 5.32 percent over the period 2014-2019. Cov......
$3000